The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)—GI-SCREEN 2013-01-CRC sub-study.
 
Takeshi Kajiwara
No Relationships to Disclose
 
Kohei Shitara
No Relationships to Disclose
 
Tadamichi Denda
No Relationships to Disclose
 
Satoshi Yuki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Taiho Pharmaceutical; Takeda
 
Takao Tamura
No Relationships to Disclose
 
Kenta Kawasaki
No Relationships to Disclose
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Takako Eguchi Nakajima
Honoraria - Chugai Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Merck; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Research Funding - Amgen Astellas BioPharma; AstraZeneca; Chugai Pharma; Merck; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Ken Kato
No Relationships to Disclose
 
Kiwamu Akagi
No Relationships to Disclose
 
Taito Esaki
No Relationships to Disclose
 
Naohiro Okano
Honoraria - Yakult Honsha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Toshihiro Kudo
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Chugai Pharma; Lilly Japan; Merck; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Lilly; Taiho Pharmaceutical
 
Hiromichi Ebi
No Relationships to Disclose
 
Yoshiyuki Yamamoto
No Relationships to Disclose
 
Satoshi Fujii
No Relationships to Disclose
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly Japan; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
 
Takayuki Yoshino
No Relationships to Disclose